Cytek Biosciences, Inc.
CTKB
$4.14
-$0.03-0.72%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -6.40M | -11.25M | -6.02M | -10.16M | -17.56M |
Total Depreciation and Amortization | 11.42M | 10.91M | 10.49M | 10.17M | 9.92M |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 10.18M | 12.74M | 13.20M | 23.51M | 22.22M |
Change in Net Operating Assets | 3.00K | 8.90M | 7.71M | 9.37M | 846.00K |
Cash from Operations | 15.20M | 21.30M | 25.38M | 32.89M | 15.43M |
Capital Expenditure | -4.33M | -3.81M | -3.53M | -4.13M | -4.45M |
Sale of Property, Plant, and Equipment | 268.00K | 321.00K | 288.00K | 97.00K | 76.00K |
Cash Acquisitions | -471.00K | -471.00K | -471.00K | -236.00K | -237.00K |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -81.67M | -63.81M | -79.27M | 13.80M | 73.07M |
Cash from Investing | -86.20M | -67.77M | -82.97M | 9.53M | 68.46M |
Total Debt Issued | 4.87M | 3.48M | 4.18M | 1.40M | 1.39M |
Total Debt Repaid | -1.94M | -1.94M | -557.00K | -558.00K | -556.00K |
Issuance of Common Stock | 1.79M | 2.25M | 2.72M | 3.11M | 3.41M |
Repurchase of Common Stock | -34.59M | -32.77M | -22.17M | -49.89M | -46.37M |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -29.87M | -28.98M | -15.82M | -45.94M | -42.13M |
Foreign Exchange rate Adjustments | -1.57M | 1.61M | 4.53M | 2.19M | 4.61M |
Miscellaneous Cash Flow Adjustments | -1.00K | -- | -- | -- | -- |
Net Change in Cash | -102.45M | -73.84M | -68.89M | -1.33M | 46.37M |